CureVac seeks to accelerate vaccine infringement case against Pfizer and BioNTech
CureVac is going on the offensive against Pfizer and BioNTech, saying that it will seek to accelerate its litigation around patents related to the manufacture of the Covid-19 vaccine Comirnaty.
The German biotech company announced Friday that the case, which originally launched in the US last summer, has been transferred from the federal district court of Massachusetts to the eastern district court in Virginia as part of an effort to speed up the litigation, potentially allowing for a trial as soon as next year.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters